Stem-cell transplantation in multiple myeloma

被引：15

作者：

Harousseau, JL ^{[1
]}

Moreau, P

Attal, M

Facon, T

Avet-Loiseau, H

机构：

[1] Hop Hotel Dieu, Dept Hematol, Nantes, France

[2] CHU Purpan, Dept Hematol, Toulouse, France

[3] Hop Claude Huriez, Dept Hematol, Lille, France

[4] Hop Hotel Dieu, Hematol Lab, Nantes, France

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2005年 / 18卷 / 04期

关键词：

multiple myeloma; autologous stem-cell transplantation; allogeneic stem-cell transplantation; reduced-intensity allogeneic transplantation;

D O I：

10.1016/j.beha.2005.01.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In patient with newly diagnosed multiple myeloma (MM), randomized studies have shown that autologous stem-cell transplantation (ASCT) is superior to conventional chemotherapy, and ASCT is now standard care, at least for younger patients. The best conditioning regimen is melphalan 200 mg/m(2), and the best stem-cell source is unselected peripheral progenitor cells. Recent results of the IFM94 trial show that double ASCT is superior to single ASCT at least in patients who do not achieve a 90% response after one transplant. By combining biologic markers (beta(2)-microglobulin, albumin) and genetic markers (hypodiploidy, chromosome 13 deletion) it is possible to accurately predict prognosis after ASCT The results of allogeneic SCT remain disappointing due to a high transplant mortality. Strategies combining ASCT and reduced-intensity allogeneic SCT are currently being studied.

引用

页码：603 / 618

页数：16

共 87 条

[51]

KROGER N, 2002, P MULT MYEL 2002 TOR, P140

[52] Myeloablative treatments for multiple myeloma:: Update of a comparative study of different regimens used in patients from the Spanish Registry for Transplantation in Multiple Myeloma [J].

Lahuerta, JJ ;

Grande, C ;

Blade, J ;

Martínez-López, J ;

De la Serna, J ;

Alegre, A ;

Laraña, JG ;

Caballero, D ;

De la Rubia, J ;

Marín, J ;

Perez-Lopez, C ;

Sureda, A ;

Escudero, A ;

Cabrera, R ;

Conde, E ;

García-Ruiz, JC ;

Pérez-Equiza, K ;

Hernandez, F ;

Palomera, L ;

León, A ;

Giraldo, P ;

Solano, C ;

Bargay, J ;

San Miguel, J .

LEUKEMIA & LYMPHOMA, 2002, 43 (01) :67-74

[53] Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: Positive selection and transplantation of enriched CD34(+) cells to remove circulating tumor cells [J].

Lemoli, RM ;

Fortuna, A ;

Motta, MR ;

Rizzi, S ;

Giudice, V ;

Nannetti, A ;

Martinelli, G ;

Cavo, M ;

Amabile, M ;

Mangianti, S ;

Fogli, M ;

Conte, R ;

Tura, S .

BLOOD, 1996, 87 (04) :1625-1634

[54]

Lenhoff S, 2000, BLOOD, V95, P7

[55] The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma [J].

Lokhorst, HM ;

Wu, KL ;

Verdonck, LF ;

Laterveer, LL ;

Van de Donk, NWCJ ;

van Oers, MHJ ;

Cornelissen, JJ ;

Schattenberg, AV .

BLOOD, 2004, 103 (11) :4362-4364

[56] Partially T-Cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: A prospective evaluation of patients treated in the phase III study HOVON 24 MM [J].

Lokhorst, HM ;

Segeren, CM ;

Verdonck, LF ;

van der Holt, B ;

Raymakers, R ;

van Oers, MHJ ;

Barge, RMY ;

Schouten, HC ;

Westveer, PHM ;

Steijaert, MMC ;

Cornelissen, JJ ;

Sonneveld, P .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1728-1733

[57] Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma [J].

Maloney, DG ;

Molina, AJ ;

Sahebi, F ;

Stockerl-Goldstein, KE ;

Sandmaier, BM ;

Bensinger, W ;

Storer, B ;

Hegenbart, U ;

Somlo, G ;

Chauncey, T ;

Bruno, B ;

Appelbaum, FR ;

Blume, KG ;

Forman, SJ ;

McSweeney, P ;

Storb, R .

BLOOD, 2003, 102 (09) :3447-3454

[58]

MCELWAIN TJ, 1983, LANCET, V2, P822

[59] Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma [J].

Moreau, P ;

Milpied, N ;

Mahé, B ;

Juge-Morineau, N ;

Rapp, MJ ;

Bataille, R ;

Harousseau, JL .

BONE MARROW TRANSPLANTATION, 1999, 23 (10) :1003-1006

[60] A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma [J].

Moreau, P ;

Harousseau, JL ;

Wijdenes, J ;

Morineau, N ;

Milpied, N ;

Bataille, R .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (03) :661-664

← 1 2 3 4 5 6 7 8 9 →